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ABSTRACT 
BACKGROUND: Modern day periodontics aims at maintaining the health of teeth 
and their supporting structures with the main goal of controlling the infection and 
regenerating the lost supporting structures. Bovine porous bone mineral is a Xenograft 
and they induce bone formation through osteoinductive property. One of the recent 
approaches is to enhance the bone graft healing by growth factors. Concentrated 
growth factor (CGF), an advanced second generation platelet concentrate is a rich 
autologous source of various growth factors and leukocytes and has a strong potential 
to influence the cellular mechanisms responsible for periodontal regeneration. 
AIM: Aim of the present study is to evaluate, the effectiveness of Concentrated 
growth factor in combination with Bovine porous bone mineral as compared to 
Bovine porous bone mineral alone in the treatment of periodontal intrabony defects. 
MATERIALS AND METHODS: A total number of 20 intrabony defects in 10 
systemically healthy patients were selected randomly for the purpose of the study. 
After the Phase-I therapy, the defects were equally divided into two groups and 
treated with concentrated growth factor and bovine porous bone mineral and bovine 
porous bone mineral alone. Clinical parameters such as plaque index (PI), gingival 
bleeding index (GBI), probing pocket depth (PPD), and clinical attachment level 
(CAL) were recorded at baseline, 6 months and 1 year post-operatively. In both the 
groups, radiographic analysis was performed at baseline, 6 months and 1 year post 
operatively. 
RESULTS: Significant reduction in the mean probing depth and gain in clinical 
attachment level was observed in CGF=BPBM and BPBM groups as compared to 
baseline but there was no significant difference between the two groups at 6 months 
(p=0.655 and p=0.250 respectively) and 1 year (p=0.247 and p=0.70 respectively). 
Radiographically, bone fill%, bone crest change% and defect resolution% was 
significantly higher in CGF=BPBM group than BPBM group at the end of 6 months 
(p=0.005, p=0.02, p=0.019 respectively) and at 1 year (p=0.000, p=0.007, p=0.001 
respectively).  
CONCLUSION: Within the limits of the present study, it can be concluded that both 
the modalities of treatment were efficient in improving the clinical as well as 
radiographic parameters. The addition of concentrated growth factor to bovine porous 
bone mineral has demonstrated significantly successful and promising results. Thus in 
future, clinical trials with larger sample size may be employed to further explore the 
potential benefits of CGF as a grafting material. 
 
KEY WORDS: Concentrated growth factor, Bovine porous bone mineral, Intra bony 
defect, Periodontal Regeneration.   
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INTRODUCTION 
Regeneration is one of the most dominant objectives of today’s rehabilitation 
therapies. The goals of periodontal therapy is not only to arrest disease 
progression but also regeneration of structures lost due to disease
1
.  
The aims of periodontal regeneration are to obtain: (i) gain in the periodontal 
attachment and bone level of a periodontally compromised tooth; (ii) a decrease in 
pocket depth; and (iii) no, or a minimal gingival recession
2
. 
Tissue loss due to periodontal disease is typically treated by using various 
regenerative procedures, including bone grafts, guided tissue regeneration (GTR) 
and growth factors, to regenerate the tooth’s supporting tissues3. 
An ideal graft material is the one that is osteoinductive, easy to manipulate, 
absorbable, abundant and easily available. Bovine porous bone mineral (Bio‑Oss 
Collagen) is one of the material used in periodontal regeneration. It is prepared by 
protein extraction of bovine bone which is similar in structure to human 
cancellous bone and has the ability to enhance bone formation
4
. 
Platelets are the major resource of autogenous growth factors which are the 
first cells to reach a wound site to initiate the healing process
5
. 
Platelets are known to release high quantities of growth factors such as 
Platelet-derived growth factor (PDGF), Transforming growth factor-β1 (TGF-β1) 
and β2 (TGF-β2), Fibroblast growth factor (FGF), Vascular endothelial growth 
factor (VEGF), and Insulin-like growth factor (IGF) 
These growth factors are deposited in the extracellular matrix and are released 
during matrix degradation and they act as a part of a complex network of signals 
with mutual effects during tissue remodeling and regeneration
6
.  
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Concentrated growth factor is an advanced 2
nd
 generation platelet concentrate 
(Sacco in 2006). It is a fibrin rich organic matrix which contains growth factors, 
platelets, leukocytes and CD34+ stem cells which help in regenerating process
7
. 
Difference in centrifugation speeds of CGF permit the isolation of a much 
larger and denser fibrin matrix richer in growth factors than typically found in 
PRP or PRF. 
It improves wound stability, which is essential for the establishment of a new 
connective tissue attachment to a root surface. It also provides a scaffold 
supporting cytokine attachment and cellular migration
8
. 
There are only limited studies available regarding the use of CGF in 
combination with various bone graft materials in periodontal regeneration. 
The purpose of this study is to evaluate the beneficial role of CGF mixed with 
bone graft to accelerate bone formation in the healing of intrabony defect areas. 
Aim and Objectives 
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AIM AND OBJECTIVES 
AIM: 
• The aim of this study is to evaluate the effectiveness of concentrated growth 
factor in combination with Bovine porous bone mineral as compared to 
Bovine porous bone mineral alone in the treatment of periodontal intrabony 
defects. 
 
OBJECTIVES: 
 The objectives of the study are: 
• To clinically evaluate and compare the use of concentrated growth factors in 
conjugation with bovine porous bone mineral and bovine porous bone mineral 
alone in the management of intrabony defects.  
• To radiographically compare and assess the regeneration of  lost alveolar 
bone by the use of concentrated growth factors in conjugation with bovine 
porous bone mineral and  bovine porous bone mineral alone in the 
management of intrabony defects. 
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REVIEW OF LITERATURE 
Periodontitis is an inflammatory disease that leads to the loss of tooth 
supporting tissues. Tissue loss caused by periodontal disease is typically managed by 
various regenerative procedures.
9
 
Regeneration is the natural renewal of a structure, produced by growth and 
differentiation of new cells and intercellular substances to form new tissues or parts. 
Regeneration occurs through growth from the same type of tissue that has been 
destroyed or from its precursor (Melcher 1976) 10. 
Periodontal regeneration is defined histologically as regeneration of the 
tooth’s supporting tissues, including alveolar bone, cementum and periodontal 
ligament over the diseased root surface
11
. 
Periodontal-regeneration is performed to improve the long-term clinical 
outcomes of periodontally compromised teeth presenting with deep pockets and 
reduced periodontal support.
12 
The ultimate goal of periodontal therapy is to regenerate periodontal tissues 
lost due to periodontitis. For this purpose bone grafts and guided tissue regeneration 
(GTR) membranes or their combinations have been used. 
12,13
 
Bone grafts are widely used to promote bone formation and periodontal 
regeneration. Bone grafts and their substitutes provide a structural framework for clot 
development, maturation and remodeling that supports bone formation in osseous 
defects.
14
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BONE GRAFTS: 
Ideal characteristics of a bone graft are: should be non-toxic, nonantigenic, 
resistant to infection, not leading to root resorption or ankylosis, strong and resilient, 
easily adaptable, readily and sufficiently available, requires minimal surgical 
procedure, stimulate new attachment and be able to trigger osteogenesis, 
cementogenesis and formation of a functional periodontal ligament.
15 
 
For any graft material to be considered as a successful regenerative material, it 
should have clear histological, clinical and radiographic evidence of the following 
criteria:
16
 
1. Biologic acceptability: the graft should not have any side effects or cause any 
unwanted tissue reaction. 
2. Resorbability: the graft should resorb slowly and be replaced by the patient’s own 
bone. 
3. Regeneration: the graft should have evidence of regenerative ability with 
formation of new bone, cementum and periodontal ligament fibers. 
4. Defect fill: the graft should have evidence of bone fill. 
5. Stability: the outcome of the treatment should be stable at reevaluation visits. 
 
A wide range of graft materials have been applied, including autografts, 
allografts, xenografts, and synthetic materials.
17 
Xenografts are obtained from vital tissues of cow or coral. Bio-Oss is a bovine 
bone that is processed by complete removal of the organic components.
18 
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Bovine Porous Bone Mineral: (BIO OSS) 
 Ideal environment for new bone formation 
 Excellent handling properties 
 Excellent osseointegration 
 Highly hydrophilic  
The unique micro- and macropore structure of Bio-Oss is an important factor 
contributing to high Hydrophilicity. The micropores ensure the high capillary action, 
and consequently the fast liquid uptake in Bio-Oss.  The interconnected macropores 
allow blood cells and proteins to enter into the Bio-Oss particles enabling effective 
osseointegration of Bio-Oss particles.
19 
 io-Oss undergoes a low heat  300     chemical extraction process by which all 
organic components are removed, but maintains the natural architecture of bone 
(Gross 1997).
21
 
When evaluating parameters such as inner surface area, porosity, crystallite size, 
and calcium to phosphorous ratio, Bio-Oss most closely resembles human cancellous 
bone as compared to DFDBA and synthetic hydroxyapatite (Giovanoli 1994
22
, 
Valdre et al. 1995
23
). 
Bio-Oss was evaluated by Chen et al. 1996
24
, with regards to its osteogenic 
potential and was found to support bone ingrowth when implanted into the muscle of 
rabbits. 
With regards to graft activity following placement, Thaller et al. (1994)
25
, found 
that Bio-Oss resorbed and underwent normal physiologic bone remodeling in the 
rabbit calvarial model. 
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Figure 1: Micro structure of bone graft (The micropores that ensure the high 
capillary action, and consequently the fast liquid uptake in Bio-Oss) 
 
 
 
 
Figure 2: Micro structure of bone graft (The interconnected macropores that allow 
blood cells, osteoblasts, osteoclasts and proteins to enter into the Bio-Oss particles 
enabling effective osseointegration of Bio-Oss particles) 
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Figure 3: Histological section of newly formed bone (The histologic assessment 
demonstrates the presence of new periodontal ligament, cementum, and bone. The 
newly formed woven bone can be observed maturting into bone trabeculae completely 
surrounding Bio-Oss particles. BO=Bio-Oss; NB=new bone L=ligament; NC=new 
cementum; OC=old cementum; D=dentin)
20
 
 
 
A - Blood serum components 
B - Geistlich Bio-Oss
® 
Figure 4: Histological section of bone matrix (A provisional matrix consisting of 
blood serum components surrounds Geistlich Bio-Oss
®
. Protein deposits are found 
between the biomaterial particles. The Geistlich Bio-Oss
®
 pores are filled with serum 
proteins and serve as a reservoir for growth factors.) 
NB 
BO 
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Clergeau et al. (1996)
26
 obtained biopsies from intrabony defects in humans 
treated with Bio-Oss plus collagen. The specimens, when analysed with the electron 
microscope, demonstrated vascular channels co-existing with osteoclastic lacunae at 
the surface and many areas of bone apposition. 
Camargo PM et al (2000)
27
conducted a controlled re-entry study on the 
effectiveness of bovine porous bone mineral used in combination with a collagen 
membrane of porcine origin in the treatment of intrabony defects in humans. Surgical 
reentry of the treated defects revealed a significantly greater amount of defect fill in 
favour of experimental sites (differences of 2.67±0.91 mm on buccal and 2.54±0.87 
mm on lingual measurements. The results of this study shows that clinical resolution 
of intrabony defects can be attained using a combination of bovine porous bone 
mineral. 
Sculean A et al (2003)
28
 compared the combination of bovine-derived 
xenograft with a bioresorbable collagen membrane to access flap surgery in deep intra 
bony defect cases. In 1 year, statistically higher PD reductions (p=40.05) and CAL 
gains (p=0.001) were found in test group than the control one. In the test group all 
sites (100%) gained minimum of 3 mm of CAL. In the control group no CAL gain 
was seen in four sites (29%), at six sites (43%) the CAL gain was of 2 mm. A CAL 
gain of 3 mm or more was noted in four defects (29%). Thus treatment with bovine 
derived xenograft and collagen membrane resulted in significantly higher CAL gains 
than treatment with access flap surgery. 
Andreas Stavropoulos (2005)
29
: in a five-year study of guided tissue 
regeneration in combination with deproteinized bovine bone (Bio-Oss) in the 
treatment of intrabony periodontal defects, the results of GTR with bioabsorbable 
membranes in combination with Bio-Oss in the treatment of periodontal intrabony 
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defects showed highly significant improvements in the parameters PD and CAL and 
are basically stable on a long-term basis. 
Galindo-Moreno et al (2014)
30
 found a correlation between CD44 expression 
and number of vessels in Anorganic bovine bone particles (ABB). Osteopontin 
expression was identified on the interstitial boundary of bone with ABB particles and 
within the osteocyte lacunae and bone canaliculi. CD44-positive cells were seen 
inside ABB particles after 6 months of graft maturation. 
 
PLATELETS & PLATELET CONCENTRATES: 
Platelets arise from cytoplasmic fragmentation of the megakaryocyte in bone 
marrow and have a lifespan of about 7 to 10 days.
31
 The platelets are responsible for 
hemostasis and are a natural source of growth factors and various cytokines.  
Ross et al 
32
 in 1974 found the regenerative potential of platelets and their role 
in wound healing. The alpha granules are the storage granules of the growth factors; 
they contain pre-packaged growth factors in an incomplete and therefore bio-inactive 
form. The growth factors proven to be contained in these granules are the three 
isomers of platelet-derived growth factor (PDGF-AA, PDGF-BB and PDGF-AB), the 
two isomers of transforming growth factor beta (TGF-β1 and TGF-β2 , vascular 
endothelial growth factor (VEGF), and epithelial growth factor (EGF). The alpha 
granules are also rich in the cell adhesion molecule vitronectin, which is required for 
osteoconduction and osseointegration.
33
  
PLATELET CONCENTRATES: 
Since 1990, medical science has recognized several components in blood, 
which are a part of the natural healing process, and when added to wounded tissues or 
surgical sites, have the potential to accelerate wound healing.  
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Fabbro et al in 2011 
34
 summarized the role of platelet concentrates as:  
1. Augmentation of tissue healing: By increased proliferation of connective tissue 
progenitor cells that stimulate fibroblast and osteoblast activity and enhance 
osteogenesis.
35
  
2. Anti-microbial activity: Against various bacterial species involved in oral 
infections. 
3. Modification of host defence mechanism: By delivering signaling peptides that 
attract macrophages.
36
  
4. Modification of immune reaction: By releasing leukocytes that synthesize 
interleukins.
37
 
 
FIBRIN GLUE  
Fibrin glue was first described in 1970 and is formed by polymerizing 
fibrinogen with thrombin and calcium, is a biomaterial that was developed in response 
to the search for improved haemostatic agents and surgical adhesives at bleeding sites 
(Gibble & Ness 1990). Thus the fibrin adhesives paved the way for the present day 
platelet concentrates. 
 
PLATELET RICH PLASMA  
The first generation platelet concentrate, which consists of a limited volume of 
plasma enriched with platelets obtained from the patient, was called platelet rich 
plasma (PRP). PRP contains growth factors such as PDGF and TGF-β that aids in 
regeneration. If a normal human blood clot contains 5% platelets, according to 
Sunitha et al 
38
,a PRP blood clot contains 95% platelets.  
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Creeper et al 
39
 in an in-vitro study reported that there was proliferation of 
PDL and osteoblastic cells under the influence of PRP. Although PRP contains 
various growth factors, their release in wound site tends to be rapid and occurs over 
extremely limited time. Also, complex process involving the use of bovine thrombin 
and other biochemical agents has limited the benefits of platelet rich plasma.
40
 
 
PLATELET RICH FIBRIN  
Platelet-rich fibrin represents a new step in the platelet gel therapeutic concept 
with simplified processing minus artificial biochemical modification. Platelet rich 
fibrin is a second and latest generation platelet concentrate, developed in France in 
2001 by Choukroun et al. It is a reservoir of autologous growth factor which attempts 
to accumulate platelets and cytokines in a physiologic fibrin clot. PRF contains 97% 
of platelets and >50% of leukocytes in a specific three dimensional distribution. It 
consists of an intimate assembly of cytokines, glycanic chains and structural 
glycoproteins enmeshed within a slowly polymerized fibrin network.
37
 
 
DIFFERENCE BETWEEN PRP & PRF 
PRP PRF 
Sudden fibrin polymerization Slow and natural polymerization 
Strong thrombin concentration Weak thrombin concentration 
Rigid network Fine, flexible fibrin network 
Condensed tetramolecular or bilateral 
junction 
Connected trimolecular or equilateral 
junctions 
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Fast elimination of incorporated platelets 
and cytokines in fibrin clot 
Glycosaminoglycans like heparin, 
hyaluronic acid enmeshed, therefore 
strong affinity for platelets and cytokines 
 
 
CONCENTRATED GROWTH FACTOR: 
Concentrated growth factor is an advanced 2
nd
 generation platelet concentrate 
(Sacco in 2006). In dentistry, many researches of growth factors related to bone 
regeneration techniques recognised that the prime tissue regenerative stimulus are 
present amongst the autologous growth factors, which have clinically proven to 
induce regeneration and tissue healing. 
PREPARATION: 
CGF is an autologous preparation withdrawn from venous blood collected in 
sterile Vacuette tubes without anticoagulant solutions. The tubes are then centrifuged 
(Medifuge, Silfradent, Sofia, Italy) with one step centrifugation protocol: 30sec -
acceleration, 2min - 2700 rpm, 4min - 2400 rpm, 4min - 2700 rpm, 3min - 3000 rpm, 
36sec – deceleration and  stop. Thus 4 different phases of CGF are obtained: 
PHASES OF CGF: 
1. Superior phase – Serum   
2. Interim phase – Fibrin buffy coat 
3. Liquid phase – Growth factors  
4. Lower  phase – Red blood cells 
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Phase 1:  
Superior phase is constituted by Serum. It is a clear straw coloured fluid and is 
the lightest and most liquid part of blood. It consists of 92% of water and 7% of other 
concentrates which includes proteins, glucides, amino acids, lipids, enzymes, 
hormones and inorganic electrolytes. It is used to secure the bleeding capillaries, wash 
the surgical site, coat and protect the regenerated portions.  
Phase 2: 
The interim phase is a fibrin buffy coat which is a polymerised fibrin block 
with 3 dimensional polymer networks of fibrinogen molecules and interwoven fibres 
united to form a single phase in the form of gel. When seen under electron microscope 
this layer is composed of thick and thin fibrillar elements. During polymerisation 
reaction the diameter of fibres increases in size until end of the reaction. During 
polymerisation it enables for volume growth of chains in all directions. The fibrin 
blocks are of higher quality as it contains high concentration of fibrinogen, factor XIII 
and thrombin. Factor XIIIa, which is activated by thrombin stabilizes the fibrin clot 
and secures it from plasmin degradation, contributing in higher fibrin tensile strength 
and stability and prolong the duration of growth factor activity, which is conducive 
for growth factor synergy & promotes cell proliferation and osteogenic 
differentiation.
8
 It is used as an autologous membrane support, filling material as a 
whole or mixed with bone particles in the defects. 
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Figure 5: Electon microscopic structure of fibrin matrix of CGF (shows CGF 
fibrin network constituted by thick & thin fibrillar elements) 
Phase 3: 
Liquid phase consists of growth factors, white blood cells and stem cells. These stem 
cells are capable of differentiating into their specialized cell types. This phase is 
mixed with autologous bone graft to acquire high performance activated graft.  
Phase 4: 
Lower phase is a dark reddish dense gel. It contains high concentration of red blood 
cells and also few white cells, platelets and clotting factors. This phase is used in pure 
form or mixed with bone grafts to fill large cavities. 
MECHANISM: 
CGF delivers various growth factors such as Platelet-derived growth factor 
(PDGF), Transforming growth factor-β1  TGF-β1  and β2  TGF-β2 , Fibroblast 
growth factor (FGF), Vascular endothelial growth factor (VEGF), Brain derived 
growth factor (BDGF) and Insulin-like growth factor (IGF) which stimulate cell 
proliferation, matrix remodelling and angiogenesis.
41
 A vitro study has demonstrated 
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that growth factors like TNF-α and  DGF had a fast kinetic release from the 
concentrate and reached its maximum accumulation in 1
st
 and 3
rd
 day respectively. 
Similarly PDGF-AB, TGF- β1 and IGF-I had a constant kinetic release and attained 
its maximum in 3
rd
 and 6
th
 day respectively. VEGF and BMP-2 showed a slow kinetic 
release and reached its maximum in 8
th
 day. These growth factors primarily play a 
role in osteoblast proliferation and differentiation.
42
 
CGF functions by degranulation of the alpha granules in platelets that consists 
of growth factors which play an important role in early wound healing.
43
 The biphasic 
platelets in CGF hastened by thrombin, influences the release of growth factors and 
other substances which improves the wound-healing process by increasing cellular 
proliferation, matrix formation, osteoid production, connective tissue healing, 
angiogenesis and collagen synthesis.  
FUNCTIONS: 
CGF is a fibrin tissue adhesive possessing haemostatic and tissue sealing 
properties. It accelerates wound healing and enhances osteogenesis. The CGF 
promotes the wound stability, which is vital for the establishment of a new connective 
tissue attachment to a root surface. It also delivers a scaffold supporting cytokine 
attachment and cellular migration and functions as a carrier for growth factors. It is an 
potent surgical haemostatic agent, induces epithelial, endothelial and epidermal 
regeneration and decreases dermal scarring. Possess antimicrobial effect as it contains 
high concentration of leukocytes. Possess anti-angiogenic property on chronic non 
healing wounds. 
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APPLICATIONS: 
CGF has broad range of healing property in patients undergoing cosmetic 
surgeries. The treatment is evidently successful in all aspects of facial aesthetics such 
as Mesotherapy as well as non-surgical facial augmentation, lips enhancement and lip 
line coutour, treating smile lines, the forehead, cheeks, neck décolletage, and other 
unwanted folds and wrinkles on the face in indistinguishable to dermal fillers. 
However attaining natural results not involving the injection of foreign chemical 
substances into the skin is the most important part in this therapy.  
In dentistry CGF is used to: 
• To fill extraction sockets (Tadic et al 2014)44 
• To fill the cavity after cystectomy (Mirkovic et al 2015)45 
• In sinus lift procedure (Kim et al 2014)46 
• Can be used alone in Recession coverage (Dogan et al 2015)47 
• With autologous bone particles or biomaterials in bone defects (Gheno et al 
2014)
48
 
• In implants to accelerate bone integration (Yang LM et al 2015)49 
 
STUDIES: 
Piemontese et al (2008)
50
 conducted a randomized, double-masked, clinical 
trial to compare platelet-rich plasma (PRP) combined with a demineralized freeze-
dried bone allograft (DFDBA) to DFDBA mixed with a saline solution in the 
treatment of human intrabony defects in 60 systemically healthy patients. Clinical and 
radiographic measurements were recorded at baseline and at the 12-month evaluation. 
Treatment with a combination of PRP and DFDBA resulted in significantly greater 
clinical improvement in intrabony periodontal defects compared to DFDBA with 
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saline. No statistically significant differences were seen in the hard tissue response 
between the two treatment groups, which confirmed that PRP had no effect on hard 
tissue fill or gain in new hard tissue formation. 
 
Manmeet Kaur et al (2010)
51
 compared the efficacy of platelet rich plasma 
(PRP) associated with bioactive glass (BG) and BG alone in the treatment of 
periodontal intrabony defects. At 6 months after treatment, the PRP/BG group 
presented a mean PPD reduction of 3.4±1.4 mm, CAL mean gain of 4.3±1.3 mm, and 
defect fill of 3.5±1.0 mm. The BG group presented a mean PPD reduction of 2.6±1.1 
mm, mean CAL gain of 3.3±1.3 mm, and defect fill of 3.1±1.2mm. Both treatment 
modalities resulted in significant PPD reduction, CAL gain and defect fill. The 
combination of PRP with a BG graft material appeared to add some benefits to the 
improvement of the clinical parameters in the treatment of intrabony defects. 
Pradeep et al 
52
 in 2011 in their clinical trial compared autologous platelet 
rich fibrin to open flap debridement alone in treatment of 3-wall intrabony defects in 
chronic periodontitis patients. The mean reduction in probing depth recorded in test 
group (4.55 ± 1.87 mm) was greater than control group (3.21 ± 1.64 mm) while mean 
PAL gain recorded was also greater in test group (3.31 ± 1.76 mm) compared to 
controls (2.77 ± 1.44 mm). Moreover, significantly greater percentage of mean bone 
fill was seen in the test group (48.26 ± 5.72 %) compared to control (1.80 ± 1.56 %).  
Thorat et al 
53
 in 2011 performed a controlled clinical trial in order to 
estimate the clinical effects of autologous PRF in treatment of intra-bony defects. All 
the clinical parameters and radiographic parameters reported greater improvement 
with the use of PRF. Significant reductions in probing depth, CAL gain and greater 
intrabony defect fill was observed.  
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Lekovic et al 
54
 in 2012 compared PRF and bovine porous bone mineral 
versus PRF alone in the treatment of intrabony periodontal defects. The results of this 
study indicated that PRF had the ability to augment the effects of PRF in reducing 
pocket depth, improving clinical attachment levels and promoting defect fill. 
Pradeep et al 
55
 in 2012 combined porous hydroxyapatite graft with platelet 
rich fibrin in management of intrabony defects in chronic periodontitis patients to 
explore the additional effectiveness of autologous PRF with bone graft material. On 
evaluation HA addition to PRF increased the regenerative effects than observed with 
PRF alone. 
Borsani et al (2015)
56
 conducted a study to assess the biological rationale for 
the use of CGF, by evaluating blood cell localization, the in vitro cumulative release 
of seven growth factors (PDGF-AB, VEGF, TNF-α, TGF-β1,  DNF,  MP-2 and 
IGF-1), it’s in vitro  effects on cell proliferation and its mechanical behaviour. The 
results indicated that platelets and leukocytes were present in a very thin space called 
“buffy coat”, localized between the white and red part of  GF. Each growth factor 
appraised, had a specific kinetic release with a great variability among subjects. The 
in vitro cell proliferation was excited.  GF showed an “apparent plasticity” and its 
mechanical response was determined by fibrin network structure. These findings 
support the  GF’s clinical use and will allow us to better interpret and refine the 
clinical outcomes. 
Bozkurt Dogan et al (2015)
47
 studied the clinical effect of concentrated 
growth factor (CGF) in combination with coronally advanced flap (CAF) compared to 
CAF alone for the treatment of multiple adjacent gingival recessions(GRs) in 20 
patients with Miller’s class I and class II recession. The results obtained were mean 
root coverage (MRC) of 82.06% and 86.67%, complete root coverage (CRC) of  
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45.8% (27/59) and 56.7% (34/60) for CAF and CAF + CGF, respectively at 6th 
month. This study suggests that use of CGF + CAF may improve the success of GRs 
since there is a significant increase in KGW and GT. 
Chandradas ND et al 2016
57
 evaluated the efficacy of platelet rich fibrin 
(PRF) with or without bone graft [demineralized bone matrix (DBM) graft] in the 
treatment of intrabony defects based on clinical and radiographic parameters in 36 
patients. Results showed that the mean reduction of PD and gain in RAL were greater 
in group A (4.25 ± 1.48, 3.92 ± 0.90) and group B (3.82 ± 0.75, 3.27 ± 0.65) than 
control (3.00 ± 1.21, 2.25 ± 0.62). Furthermore, statistically significant improvement 
in LBG and %BF was found in group A (3.47 ± 0.53, 61.53 ± 4.54) compared to 
group B (2.55 ± 0.61, 49.60 ± 14.08) and group C (1.21 ± 0.80, 24.69 ± 15.59).  The 
study showed that PRF enhances clinical and radiological parameters compared to 
OFD alone in intrabony defects. Addition of DBM increases the effects of PRF in 
RAL gain and radiographic defect fill. 
J.Qiao (2016)
58
 investigated the effect of CGFs on proliferation and alkaline 
phosphatase (ALP) activity of human periodontal ligament cells (hPDLCs) in vitro. 
As bone homeostasis was fundamentally controlled by Wnt-mediated signals, they 
investigated Wnt3a expression of hPDLCs after treatment of CGFs. Results revealed 
that CGFs significantly promoted the proliferation and ALP activity of hPDLCs, and 
the effects seem more stimulatory compared to rhPDGF-AB and rhTGF-β1 
combination. This was the first report Wnt3a expression by hPDLCs after treated by 
 GFs. This indicated the participation of Wnt/β-catenin signaling in CGFs inducing 
cell proliferation and differentiation in early phase.  
Pirpir et al (2017)
59
 evaluated the effectiveness of concentrated growth factor 
on osseointegration in twelve patients in maxillary anterior region. The mean ISQ 
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values recorded were 79.40 ± 2.604 in the study group and 73.50 ± 5.226 in the 
control group at 1st week, 78.60 ± 3.136 in the study group and 73.45 ± 5.680 in the 
control group at 4th week. The differences between the two groups were seemed to be 
statistically significant (p < 0.05). The results showed that the concentrated growth 
factor had positive effects on implant stabilization. The ISQ measurements at week 1 
and week 4 were markedly higher in the study group. Application of this material 
seems to promote osseointegration. 
Xia Chen et al (2018)
60
 studied the effect of Concentrated Growth Factor 
(CGF) on the Promotion of Osteogenesis in Bone Marrow Stromal Cells (BMSC) in 
vivo. This study demonstrated that CGF not only promotes the superior osteoinductive 
activity of BMSCs to enhance bone formation, but also outperforms collagen in 
stimulating angiogenesis. This study concluded that CGF is an excellent cell growth 
factor biomaterial. Combined with BMSCs, it had a strongly positive effect on both 
osteogenesis and angiogenesis, making it a very promising material for bone 
regeneration. 
Shebin Hong et al (2018)
61
: In a Comparative Evaluation of Concentrated 
Growth Factor and Platelet-rich Fibrin on the Proliferation, Migration, and 
Differentiation of Human Stem Cells of the Apical Papilla. The objective of this study 
was to assess their effects on the proliferation, migration, and differentiation of human 
stem cells of the apical papilla (SCAPs). From the results obtained they concluded 
that both CGF and PRF can stimulate the proliferation, migration, and differentiation 
of SCAPs. CGF may be a potential alternative in regenerative endodontics. 
Forabosco, et al (2018)
62
 conducted a clinical study was to examine the effect 
of concentrated growth factors matrix (CGFm) on implant survival rate in augmented 
sinuses; the secondary aim was to evaluate the effect of CGFm on sinus augmentation 
Review of literature 
 
22 
 
postoperative morbidity in fifty patients. Of these, 25 patients (control‑group) 
received a corticocancellous xenograft. The other 25 patients (test group) received a 
mixture of 70% CGF matrix and 30% corticocancellous xenograft. Results showed 
96.4% survival rate was described in the test group (with CGFm) and a 96.1% 
survival rate in the control group (without CGFm). No statistically significant 
differences were observed between the survival rates of the two groups after 1 year. 
This study concluded that the mixture of CGFm (70%) with xenograft (30%) is an 
alternative to xenograft material alone and is a predictable procedure resulting in less 
postoperative morbidity in sinus augmentation. 
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MATERIALS AND METHOD 
SOURCE OF DATA: 
The study population will be selected from the outpatient sections of the 
Department of Periodontics, TNGDC and Hospital, Chennai. 
INCLUSION CRITERIA: 
1. Patients within the age group 20 - 60 years of either gender  
2. Patients with probing depth ≥ 5mm following Phase-I therapy  
3. Radiographic evidence of vertical / angular bone loss bilaterally. 
4. Systemically healthy patients  
5. Patients willing for voluntary participation & have signed informed consent  
EXCLUSION CRITERIA: 
1. Patients showing poor oral hygiene maintenance after Phase-I therapy  
2. Patients with known systemic diseases/ metabolic disorders  
3. Patients under any medication 
4. Patients using tobacco or tobacco related products  
5. Pregnant / Lactating women  
6. Patients with any known allergies  
 
SUBJECTS: 
A total of 10 patients diagnosed as chronic periodontitis or aggressive 
periodontitis with clinical and radiographic evidence of vertical / angular bone loss 
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bilaterally, indicated for regenerative periodontal surgery and Group A and Group B 
were randomly assigned 
Group A: Receiving Concentrated growth factor with Bovine porous bone mineral 
Group B: Receiving Bovine porous bone mineral alone  
STUDY DESIGN: 
In this clinical study the participants were recruited prospectively. 
SEX: Either sex 
STUDY PROTOCOL:  
1. Patient selection as per the inclusion & exclusion criteria.  
2. Purpose of the study explained to the subjects. (Annexure 1 & 2) 
3. Medical history and informed consent obtained. (Annexure 3 & 4) 
4. Complete periodontal examination using a mouth mirror and UNC15 
periodontal probe under artificial light  
5. Intra-oral evaluation and periodontal examination - Clinical periodontal 
parameters namely, Plaque index, Gingival Bleeding Index, Probing 
Pocket Depth and Clinical Attachment Level  
6. Radiographic evaluation- Orthopantamogram, Intraoral periapical 
radiograph 
7. Phase I therapy and re-evaluation of clinical parameters after 4 weeks.  
8. Surgical procedure- Regenerative therapy in bilateral defect sites using 
CGF combined with bone graft and bone graft alone respectively 
9. Post-operative care.  
10. Clinical and Radiographic re-evaluations at the end of 6 and 12 months.  
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PRE-OPERATIVE CLINICAL ASSESSMENT 
CLINICAL PARAMETERS 
Using proforma (Annexure-5) case history was taken and following clinical 
parameters were evaluated at baseline and post surgically at 6
 
and 12
 
months: 
1. Plaque index (PI) 
2. Gingival bleeding index (GBI)
 
3.Probing Pocket Depth (PPD): Measured with customized acrylic stent and UNC-15 
probe 
4. Clinical attachment level (CAL) 
 
1. PLAQUE INDEX (Silness and Loe 1967)
63
 
All teeth were examined at 4 sites each (disto-facial, facial, mesio-facial 
lingual / palatal) and were scored as follows :  
Criteria for Scoring:  
Score 0 : No plaque  
Score 1: Plaque not visible to the naked eye, detected only by running the explorer or 
by using a disclosing agent  
Score 2: Thin to moderate accumulation of soft deposits within the gingival pocket or 
on tooth and gingival margin, visible to the naked eye 
 Score 3: Abundance of soft matter within gingival pocket and/or on tooth surface and 
margin, inter-dental area stuffed with soft debris  
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Calculation:  
Plaque index per tooth = Total score / 4 
Plaque index per individual = 
                  
                              
 
Interpretation:  
 
 
 
 
 
2. GINGIVAL BLEEDING INDEX: (Ainamo & Bay 1975)
64 
Starting distobuccally, the probe was inserted slightly into the sulcus and run 
to the buccal and mesial surfaces of every tooth at an angle of about 45°. This was 
repeated for all teeth present. Probing was similarly carried out at palatal/lingual sites. 
Any gingival units that exhibited bleeding were recorded. The total number of 
bleeding sites per tooth was thus recorded for every tooth except the third molar.  
Criteria for Scoring: 
Positive score (1) - Presence of bleeding within 30 seconds  
Negative score (0) - Absence of bleeding 
 % of bleeding sites = 
                                     
                                     
 
Score 0 Excellent oral hygiene 
0.1 to 0.9 Good oral hygiene 
1.0 to 1.9 Fair oral hygiene 
2.0 to 3.0 Poor oral hygiene 
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STENT PREPARATION  
Acrylic occlusal stents were fabricated over the study models. Self cure acrylic 
was used for this purpose. The stent covered the occlusal and coronal 1/ 3rd of the 
labial and lingual surfaces of the teeth. Vertical grooves were given to guide the probe 
placement in the same plane and direction repeatedly during measurements to avoid 
any variation. The recordings were made using a UNC 15 periodontal probe. 
3. PROBING POCKET DEPTH (PPD)
65
  
A customized acrylic stent was prepared and stored in the cast itself. The base 
of the stent served as a reference point (RP) to take the measurements. Probing depth 
was calculated by measuring the distance from a fixed reference point on the stent to 
the base of the pocket (BP) along the groove using a UNC-15 periodontal probe and 
subtracting it by the distance from the fixed reference point to the gingival margin 
(GM).  
4. CLINICAL ATTACHMENT LEVEL (CAL)
65
 
Clinical attachment level was calculated by measuring the distance from a 
fixed reference point on the stent to the base of the pocket (BP) along the groove 
using a UNC-15 periodontal probe and subtracting it by the distance from the fixed 
reference point to the cemento enamel junction (CEJ) 
 
RADIOGRAPHIC PARAMETERS  
Intraoral periapical radiographs were taken with radiographic grid for each site 
using long cone paralleling technique and XCP holders at baseline and post surgically 
at6 months and 1 year.  
All radiographs were digitalized using digital camera and transferred to the 
computer as JPEG image. To measure the linear radiographic defect depth (DD) in 
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millimetre (mm), ImageJ software designed for image analysis by National Institute 
of Health (NIH) was used.  
The following anatomical landmarks of the intrabony defect were identified on 
the radiograph images based on the criteria set by Bjorn et al 
66
 and by Schei et al 
67
:  
1. CEJ: The cemento-enamel junction of the tooth with the intrabony defect.  
2. AC: The most coronal position of the alveolar bone crest of the intrabony defect 
when it touches the root surface of the adjacent tooth before treatment. (The top of the 
crest)  
3. BD: The most apical extension of the intrabony defect where the periodontal 
ligament space still retained its normal width before treatment. (The bottom of the 
defect) 
If restorations were present, the apical margin of the restoration was used to replace 
the CEJ as a fixed reference point. 
The following linear measurements were made
68,69 
1. CEJ to bottom of the defect (CEJ to BD) = Defect Depth (DD)  
2. CEJ to most coronal extent of the alveolar crest (CEJ to AC)  
3. Depth of the intrabony defect at baseline = (CEJ to BD) - (CEJ to AC) 
4. CORRECTION FACTOR (CF): In order to estimate distortion between the 
consequent radiographs, an anatomically non-variable distance i.e., the root length 
[distance from the CEJ to the root apex (CEJ to RA)] was measured on all the 
radiographs. The correction factor (CF) was calculated as follows
69
 
 
Correction Factor = CEJ to RA (baseline)  
                                   CEJ to RA (post-op)  
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In cases where it was not possible to measure the root length, the crown length was 
measured. (Distance from the cusp tip to the CEJ).  
5. Bone fill (BF) = CEJ to BD (baseline) - [CEJ to BD (post op) x CF]  
6. Bone fill percentage (BF %) = Bone fill x 100  
                                                      Defect Depth (at baseline)  
7. Bone crest change (BCC) = CEJ to AC (baseline) - [CEJ to AC (post op) x CF] 
8. Bone crest change percentage (BCC%) = Bone Crest Change x 100  
                                                                         CEJ to AC (baseline)  
If the results were negative, this means that a process of bone resorption had 
occurred.
69
  
9. Amount of original defect resolution (DR) = Bone fill (BF) - bone crest change 
(BCC)  
10. Percentage (%) of original defect resolution (DR%) = Defect Resolution x 100  
                                                                                     Depth of intrabony defect (BL)  
All the above mentioned observations were recorded and subjected to statistical 
analysis. 
ARMAMENTARIUM: 
FOR CLINICAL EXAMINATION: 
1. Patient drape 
2. Mouth mirror  
3. UNC 15 probe 
4. Kidney tray 
5. Cotton roll 
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6. Sterilized disposable gloves, head cap, facemask 
7. Customized  acrylic  stents   
8. Intraoral periapical radiograph film 
9. Radiographic grid. 
FOR PHASE I THERAPY: 
1. Patient drape 
2. Mouth mirror 
3. UNC 15 probe  
4. Kidney tray 
5. Cotton rolls 
6. Saline 
7. Gauze 
8. Sterilized disposable gloves, head cap, facemask 
9. Sterile disposable syringes 
10. Ultrasonic scaler 
11. Local anaesthetic solution (2% lignocaine hydrochloride with adrenaline 
1:80000) 
12. Gracey Curettes 
FOR SURGICAL PHASE: 
1. Patient drape 
2. Mouth mirror  
3. UNC 15 probe 
4. Dental tweezers  
5. Sterile surgical gloves  
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6. Disposable facemask  
7. Local anaesthetic solution (2% lignocaine hydrochloride with adrenaline 
1:80000) 
8. Sterilised disposable syringes  
9. Bard parker blade no 15 and 15C 
10. Bard parker blade handle straight and contra-angled  
11. Periosteal elevator  
12. A set of  Gracey’s curettes  
13. Schlugler and Sugarman bone files  
14. Straight and Curved scissors  
15. Saline  
16. Gauze  
17. Dapen dish  
18. Bovine porous bone mineral  
19. Suture material 3-0 black silk braided  
20. Needle holder  
21. Cement spatula and Glass slab  
22. Periodontal dressing (Coe pacTM) 
FOR CGF PREPARATION AND COLLECTION: 
1. Sterile cotton and surgical spirit  
2. Sterile disposable syringe (9 ml)  
3. Tourniquet  
4. Sterile 10 ml test tubes  
5. Centrifuge  
6. Dental tweezers  
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METHOD: 
PRESURGICAL PROCEDURES AND INVESTIGATIONS: 
 Clinical case history record and clinical photographs of the site of interest. 
 Clinical probing pocket depth was assessed with customized acrylic stents to 
help reproducibility of probe placement  
 Intraoral periapical radiographs using long cone paralleling technique and 
radiographic grid. 
 Phase I therapy, that included oral hygiene instructions, scaling and root 
planing using hand and ultrasonic instruments, were performed. Adjunctive 
chemical plaque control in the form of chlorhexidine mouthwash 0.12% twice 
daily was advised. 
 Routine haematological investigations was performed 
SURGICAL PROCEDURE: 
Intra-oral antisepsis and extra-oral antisepsis were performed with 0.2% 
chlorhexidine digluconate rinse and 5% povidone iodine solution respectively. The 
surgical site was anaesthetized with 2% Lignocaine HCl with adrenaline (1:80,000) 
using block or infiltration techniques. Then crevicular incisions were made using Bard 
Parker blade No.15 on the facial and lingual/palatal surfaces, extending to one tooth 
on either side of the defect.  
A full thickness mucoperiosteal flap was carefully reflected using the 
periosteal elevator. After flap reflection and exposure of the osseous defect, a 
thorough debridement of soft and hard tissue was done using the area specific Gracey 
curettes. Debridement was followed by copious irrigation with 0.9% normal saline. 
Presuturing was done prior to placement of bone graft.  
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In Group A, the defect was filled with a combination of  Bovine porous bone mineral 
(BPBM) and Concentrated growth factors (CGF). 
In Group B, the defect was filled with  Bovine porous bone mineral (BPBM) mixed 
with saline.  
CGF PREPARATION: 
59
 
CGF was produced as follows: 9 ml of blood was drawn in sterile test tubes 
without anticoagulant solutions. These tubes were then immediately centrifuged using 
a program with the following characteristics: 30 seconds acceleration, 2400 - 2700 
rpm for 12 minutes and 36 seconds deceleration and stop.  At the end of the process, 
four blood fractions were created: A superior phase represented by the serum (blood 
plasma without fibrinogen and coagulation factors, platelet poor plasma, PPP); an 
interim phase represented by a very large and dense polymerized fibrin block 
containing the CGFs; third layer containing white blood cells and stem cells; and the 
lower RBC layer. The fibrin block (interim phase) and RBC layer (lower phase) 
beneath it was cut into pieces of 1∼2 mm, and mixed with Bovine porous bone 
mineral granules at a relative volume of 1:1 and homogenized.  
The mixture was then placed into the osseous defect with light pressure and 
filled upto the most coronal level of osseous defect. The mucoperiosteal flaps were 
then repositioned and secured using 3-0 black braided silk sutures. Periodontal 
dressing (Coe-pacTM) was placed. 
 
POST OPERATIVE INSTRUCTIONS 
 Suitable antibiotics and analgesics were prescribed. 
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 The patient was instructed to continue regular home hygiene care, except in 
the operated area, in which tooth brushing was discontinued for 14 days after 
surgery and plaque control was maintained by means of gentle topical 
applications of cotton swabs saturated with 0.12% chlorhexidine gluconate 
twice a day. Gentle tooth brushing with an extra soft‑bristle toothbrush 
(Postsurgical toothbrush) using Charter’s method was then initiated after 14 
days. 
 Periodontal dressings and sutures were removed 14 days after surgery 
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Photograph 1A: SURGICAL ARMAMENTARIUM 
 
 
Photograph 1B: SURGICAL ARMAMENTARIUM 
 
  
Photographs 
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Photograph 2: ARMAMENTARIUM FOR CGF PREPARATION 
 
 
Photograph 3: COLLECTION OF BLOOD SAMPLE 
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Photograph 4: MEDIFUGE CENTRIFUGE FOR CGF PREPARATION 
 
 
Photograph 5: PHASES OF CGF 
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Photograph  6: BOVINE POROUS BONE MINERAL (BIO-OSS
®
) 
 
 
Photograph 7: SEPARATION OF PHASE 2 & PHASE 3 OF CGF 
 
 
Photograph 8: HOMOGENISED MIXTURE OF CGF AND BIO-OSS
®
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GROUP A 
Photograph 9: PREOPERATIVE VIEW 
 
Photograph 10: INTRABONY DEFECT EXPOSURE 
 
Photograph 11: PLACEMENT OF CGF + BIO-OSS MIXTURE 
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GROUP B 
Photograph 12: PREOPERATIVE VIEW 
 
Photograph 13: INTRABONY DEFECT EXPOSURE 
 
Photograph 14: PLACEMENT OF BIO-OSS + 0.9% SALINE MIXTURE 
 
 
Photographs 
 
41 
 
Photograph 15: 
6 MONTHS POST OPERATIVE VIEW - GROUP A 
 
 
Photograph 16: 
6 MONTHS POST OPERATIVE VIEW - GROUP B 
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Photograph 17: 
1 YEAR POSTOPERATIVE VIEW - GROUP A 
 
 
Photograph 18: 
1 YEAR POSTOPERATIVE VIEW - GROUP B 
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Photograph 19: XCP HOLDERS AND IOPA GRID 
 
 
 
 
Photograph 20: MARKING OF RADIOGRAPHIC LANDMARKS 
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GROUP A 
Photograph 21A: PREOPERATIVE IOPA 
 
Photograph 21B: 6 MONTHS POSTOPERATIVE IOPA 
 
Photograph 21C: 1 YEAR POSTOPERATIVE IOPA 
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GROUP B 
Photograph 22A: PREOPERATIVE IOPA 
 
Photograph 22B: 6 MONTHS POSTOPERATIVE IOPA 
 
Photograph 22C: 1 YEAR POSTOPERATIVE IOPA 
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ANALYSIS OF RADIOGRAPHIC IMAGE WITH IMAGEJ SOFTWARE 
 
Photograph 23A: SETTING SCALE OF 1mm PER RADIOGRAPHIC GRID 
 
 
Photograph 23B: MEASUREMENT OF DEFECT 
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STATISTICAL ANALYSIS 
Statistical Analysis was carried out using Statistical software SPSS (Statistical 
Package for Social Science) Version 16 (IBM Corp, Chicago, IL, USA). 
  Quantitative data was assessed for normality using Shapiro Wilk’s Test.  
Intra group comparisons for parametric data (Plaque index, Gingival bleeding 
index, Periodontal probing depth and Clinical attachment level) between baseline, 6 
months, 1 year was carried out using Repeated Measures ANOVA.  
Intra group comparisons for parametric data (Bone Fill%, Bone crest 
change%, and Defect resolution%) between 6 months and 1 year was conducted using 
Paired Sample t Test.  
Intergroup comparison of all the parametric data was carried out using 
Independent Sample t Test. 
P ≤0.05 was evaluated as significant in the present study. 
 
REPEATED MEASURES ANOVA 
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PAIRED SAMPLE t TEST FORMULA 
 
 
INDEPENDENT SAMPLE t TEST FORMULA: 
 
 
p value: 
The p value or calculated probability was the estimated probability of 
rejecting the null hypothesis (H0) of a study question when that hypothesis was true. 
The smaller the p-value, the more significant the result was said to be. In this study all 
the p-values are two tailed and confidence intervals were calculated at the 95% level. 
Differences between the two populations were considered significant when p ≤ 0.05. 
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RESULTS 
The present study was carried out with the aim to evaluate, the effectiveness of 
concentrated growth factor in combination with Bovine porous bone mineral as compared 
to Bovine porous bone mineral alone in the treatment of periodontal intrabony defects 
both clinically and radiographically. All the patients who were enrolled in the study 
returned for scheduled maintenance visits. A total of 10 patients and 20 sites exhibiting 
radiographic vertical / angular osseous defects within the age group of 20-60 years were 
selected for the study. The final results and statistical analysis was done for a total of 20 
sites, 10 sites in each group. 
In Group A, the defect was filled with a combination of Bovine porous bone mineral 
(BPBM) and Concentrated growth factors (CGF). 
In Group B, the defect was filled with Bovine porous bone mineral (BPBM) mixed with 
saline.  
All patients showed good compliance and healing period was uneventful for both 
the groups, without any signs of infections and complications, indicating biocompatibility 
of both grafting modalities. The observations and results of various parameters are 
summarized in the tables and figures. Master chart observations of clinical parameters are 
listed in table 1 and 2 with mean ± SD values and intragroup and intergroup comparisons 
in table 5, 6 and 7 respectively. Master chart observations of radiographic parameters are 
listed in table 3 and their mean ± SD, correction factor values, intragroup and intergroup 
comparisons are listed in table 4, 8 and 9 respectively. Figures 6,7,8,9,10 and figures 
11,12,13,14 diagrammatically represent clinical and radiographic parameters respectively 
in both the groups. 
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CLINICAL PARAMETERS 
1. Plaque Index  
Intragroup comparison 
The mean plaque index score at baseline was 2.30±0.39, at 6 months was 0.88±0.27 
and at 1 year was 0.47±0.12. The mean reduction in plaque index from baseline to 6 months 
was 1.42±0.10 and from 6 months to 1 year was 0.41±0.06 which was statistically 
significant (p=0.000) at both time intervals. 
 
2. Gingival Bleeding Index  
Intragroup comparison 
The mean gingival bleeding index percentage value was 76.83±6.55, at 6 months 
was 21.02±6.58 and at 1 year was 9.74±2.17. The mean reduction in gingival bleeding index 
score from baseline to 6 months was 55.81±1.84 and from 6 months to 1 year was 
11.28±1.51 which was statistically significant (p=0.000) at both time intervals. 
 
3. Probing pocket depth 
Intragroup comparison 
Group A: The mean pocket depth at baseline was 8.0±2.05, at 6 months was 
3.6±1.35 and at 1 year was 2.2±0.91. The mean reduction in pocket depth from baseline 
to 6 months was 4.4±0.31 with p=0.000 and from 6 months to 1 year was 1.4±0.26 with 
p=0.002 which was statistically significant. 
Group B: The mean pocket depth at baseline was7.0±1.83, at 6 months was 
3.9±1.60 and at 1 year was 2.7±0.95. The mean reduction in pocket depth from baseline 
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to 6 months was 3.1±0.18 with p=0.000 and from 6 months to 1 year was 1.2±0.25 with 
p=0.003 which was statistically significant. 
Intergroup comparison 
The mean difference in pocket depth between Group A and Group B at baseline 
was 0.27, at 6 months was 0.66 and at 1 year was 0.25 which were statistically non-
significant (p=0.265, p=0.655 and p=0.247 respectively). 
 
4. Clinical Attachment level  
Intragroup comparison 
Group A: The mean clinical attachment level at baseline was 8.9±2.08, at 6 
months was 4.9±1.96 and at 1 year was 3.5±1.72. The mean reduction in attachment level 
from baseline to 6 months was 4.0±0.39 with p=0.000 and from 6 months to 1 year was 
1.4±0.27 with p=0.002 which was statistically significant. 
Group B: The mean clinical attachment level at baseline was 8.3±1.95, at 6 
months was 6.0±2.16 and at 1 year was 4.9±1.52. The mean reduction in attachment level 
from baseline to 6 months was 2.3±0.26 with p=0.000 and from 6 months to 1 year was 
1.1±0.28 with p=0.01 which was statistically significant. 
Intergroup comparison 
The mean difference in pocket depth between Group A and Group B at baseline 
was 0.60, at 6 months was -1.1 and at 1 year was -1.4 which were statistically non-
significant (p=0.514, p=0.250 and p=0.70 respectively). 
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RADIOGRAPHIC PARAMETERS 
1. Bone Fill  
Intragroup comparison 
Group A: The mean bone fill at 6 months was 4.52±2.01 and at 1 year was 
6.71±1.77. The mean difference in bone fill from 6 months to 1 year was 2.20 which was 
statistically significant (p = 0.000). 
Group B: The mean bone fill at 6 months was 2.33±1.11 and at 1 year was 
4.16±1.37. The mean difference in bone fill from 6 months to 1 year was 1.83 which was 
statistically significant (p = 0.001). 
Intergroup comparison 
At 6 months mean difference in bone fill between group A and group B was 2.19 
which was statistically significant (p=0.007). At 1 year mean difference in bone fill 
between group A and group B was 2.56 which was statistically significant (p=0.002). 
 
2. Bone Fill %  
Intragroup comparison 
Group A: The mean bone fill percentage at 6 months was 41.46±15.79 and at 1 
year was 62.92±11.38. The mean difference in bone fill from 6 months to 1 year was 2.14 
which was statistically significant (p = 0.001). 
Group B: The mean bone fill percentage at 6 months was 23.16±9.26 and at 1 
year was 41.52±8.97. The mean difference in bone fill from 6 months to 1 year was 1.83 
which was statistically significant (p = 0.001). 
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Intergroup comparison 
At 6 months mean difference in bone fill percentage between group A and group 
B was 18.30 which was statistically significant (p=0.005). At 1 year mean difference in 
bone fill between group A and group B was 21.40 which was statistically significant 
(p=0.000). 
 
3.Bone crest change  
Intragroup comparison 
Group A: The mean bone crest change at 6 months was 0.98±0.57 and at 1 year 
was 1.79±0.77. The mean difference in bone fill from 6 months to 1 year was 0.82 which 
was statistically significant (p = 0.000). 
Group B: The mean bone crest change at 6 months was 0.54 ± 0.29 and at 1 year 
was 1.11 ± 0.40. The mean difference in bone fill from 6 months to 1 year was 0.57 
which was statistically significant (p = 0.001). 
Intergroup comparison 
At 6 months mean difference in bone crest change between group A and group B 
was 0.44 which was statistically significant (p=0.043). At 1 year mean difference in bone 
fill between group A and group B was 0.69 which was statistically significant (p=0.022).
Results 
 
54 
 
4.Bone Crest change %  
Intragroup comparison 
Group A: The mean bone crest change percentage at 6 months was 27.39±14.90 
and at 1 year was 50.64±16.68. The mean difference in bone fill from 6 months to 1 year 
was 2.32 which was statistically significant (p = 0.000). 
Group B: The mean bone crest change percentage at 6 months was 14.08±7.14 
and at 1 year was 30.03±13.53. The mean difference in bone fill from 6 months to 1 year 
was 1.59 which was statistically significant (p = 0.002). 
Intergroup comparison 
At 6 months mean difference in bone crest change percentage between group A 
and group B was 13.31 which was statistically significant (p=0.02). At 1 year mean 
difference in bone fill between group A and group B was 20.61 which was statistically 
significant (p=0.007). 
 
5.Defect resolution: 
Intragroup comparison 
Group A: The mean defect resolution at 6 months was 3.53±1.76 and at 1 year 
was 4.92±1.39. The mean difference in bone fill from 6 months to 1 year was 1.385 
which was statistically significant (p = 0.002). 
Group B: The mean defect resolution at 6 months was 1.79±1.10 and at 1 year 
was 3.05±1.56. The mean difference in bone fill from 6 months to 1 year was 1.25 which 
was statistically significant (p = 0.009). 
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Intergroup comparison 
At 6 months mean difference in defect resolution between group A and group B was 1.74 
which was statistically significant (p=0.016). At 1 year mean difference in bone fill 
between group A and group B was 1.86 which was statistically significant (p=0.011). 
 
6.Defect resolution %  
Intragroup comparison 
Group A: The mean defect resolution percentage at 6 months was 47.76±19.12 
and at 1 year was 68.80±9.05. The mean difference in bone fill from 6 months to 1 year 
was 2.10 which was statistically significant (p = 0.004). 
Group B: The mean defect resolution percentage at 6 months was 28.31±14.31 
and at 1 year was 47.61±14.96. The mean difference in bone fill from 6 months to 1 year 
was 1.93 which was statistically significant (p = 0.009). 
Intergroup comparison 
At 6 months mean difference in defect resolution percentage between group A 
and group B was 19.44 which was statistically significant (p=0.019). At 1 year mean 
difference in bone fill between group A and group B was 21.20 which was statistically 
significant (p=0.001). 
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TABLES 
 
TABLE 1:  
MASTER CHART 1: PLAQUE INDEX AND GINGIVAL BLEEDING INDEX 
 
S.NO AGE 
(years) 
SEX 
(M/F) 
BASELINE 6 MONTHS 1 YEAR 
PI GBI% PI GBI% PI GBI% 
1 31 F 2.8 81.7 1.0 26.9 26.9 26.9 
2 33 M 2.6 79.3 0.8 21.7 21.7 21.7 
3 22 M 2.1 75.9 0.7 15.8 15.8 15.8 
4 22 M 2.1 75.9 0.7 15.8 15.8 15.8 
5 29 F 1.9 64.1 0.6 20.3 20.3 20.3 
6 48 M 2.0 83.4 1.2 27.1 27.1 27.1 
7 31 F 2.8 81.7 1.0 17.6 17.6 17.6 
8 32 F 1.7 72.5 0.5 14.2 14.2 14.2 
9 59 F 2.6 84.2 1.4 34.5 34.5 34.5 
10 33 M 2.4 69.6 0.9 16.3 16.3 16.3 
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TABLE 2: 
MASTER CHART 2: CLINICAL PARAMETERS 
 
 
S.NO 
GROUP A GROUP B 
Baseline 
(mm) 
6 months 
(mm) 
1 year 
(mm) 
Baseline 
(mm) 
6 months 
(mm) 
1 year 
(mm) 
PPD CAL PPD CAL PPD CAL PPD CAL PPD CAL PPD CAL 
1 7 8 3 4 2 3 6 7 4 6 3 5 
2 10 11 4 5 3 4 9 10 5 7 3 5 
3 8 8 3 3 2 2 6 7 3 4 2 3 
4 9 9 4 4 2 2 6 7 3 4 2 3 
5 7 7 3 4 1 2 5 7 2 4 2 4 
6 6 7 3 4 2 3 8 10 5 8 3 6 
7 9 11 4 6 3 5 9 11 5 8 3 6 
8 5 7 2 5 2 5 6 7 3 5 2 5 
9 7 8 3 4 1 2 5 6 2 4 2 4 
10 12 13 7 10 4 7 10 11 7 10 5 8 
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TABLE 3A: 
MASTER CHART 3: RADIOGRAPHIC PARAMETERS 
 
 
 
S.NO 
GROUP A 
BASELINE 
(mm) 
6 MONTHS 
(mm) 
1 YEAR 
(mm) 
CEJ – 
BD 
CEJ- 
AC 
AC –
BD 
CEJ - 
BD 
CEJ- 
AC 
AC -
BD 
CEJ - 
BD 
CEJ- 
AC 
AC- 
BD 
1 10.455 2.870 7.585 5.014 2.092 2.922 3.329 1.528 1.801 
2 12.869 3.936 8.933 6.173 2.374 3.799 4.105 1.371 2.734 
3 12.10 3.789 8.311 5.213 2.001 3.212 2.361 0.594 1.767 
4 10.211 1.810 8.401 5.332 1.736 3.596 3.632 1.245 2.387 
5 9.517 2.604 6.913 7.894 1.928 5.966 3.341 1.395 1.946 
6 8.506 2.638 5.868 4.721 1.742 2.979 3.152 1.183 1.969 
7 12.275 4.729 7.546 6.547 3.964 2.583 5.051 2.857 2.194 
8 8.273 4.283 3.99 6.931 3.617 3.314 5.274 3.242 2.032 
9 8.493 3.371 5.122 5.326 2.507 2.819 2.870 1.431 1.439 
10 13.871 5.692 8.179 10.204 4.714 5.49 7.150 3.301 3.849 
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TABLE 3B: 
MASTER CHART 4: RADIOGRAPHIC PARAMETERS 
 
 
 
S.NO 
GROUP B 
BASELINE 
(mm) 
6 MONTHS 
(mm) 
1 YEAR 
(mm) 
CEJ - 
BD 
CEJ- 
AC 
AC-
BD 
CEJ - 
BD 
CEJ- 
AC 
AC-
BD 
CEJ - 
BD 
CEJ- 
AC 
AC- 
BD 
1 9.406 3.471 5.935 7.856 3.293 4.563 5.016 2.965 2.051 
2 12.523 3.682 8.841 8.442 3.051 5.391 5.984 2.293 3.691 
3 7.816 3.00 4.816 4.845 2.542 2.303 3.896 1.529 2.367 
4 7.421 3.320 4.101 5.274 2.475 2.799 4.425 1.454 2.971 
5 8.602 3.742 4.86 7.422 3.351 4.071 5.959 3.021 2.938 
6 12.395 3.550 8.845 10.482 3.341 7.141 6.880 3.205 3.675 
7 12.429 4.928 7.501 8.026 4.397 3.629 6.891 3.902 2.989 
8 8.031 4.052 3.979 7.710 3.660 4.05 6.590 3.215 3.375 
9 8.021 3.609 4.412 6.392 2.914 3.478 4.539 2.431 2.108 
10 12.994 5.037 7.957 11.321 4.582 6.739 9.016 3.910 5.106 
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TABLE 4: 
CORRECTION FACTOR (CF) CALCULATION FOR RADIOGRAPHIC 
PARAMETERS 
GROUP A 
 
S.NO 
CEJ – RA  
CF 6 
CEJ – RA  
CF 1 
BASELINE 6 MONTHS BASELINE 1 YEAR 
1 18.62 16.94 0.91 18.62 16.20 0.87 
2 17.95 20.64 1.15 17.95 18.67 1.04 
3 18.5 15.73 0.85 18.5 16.84 0.91 
4 17.97 17.43 0.97 17.97 17.07 0.95 
5 17.6 17.78 1.01 17.6 17.6 1 
6 16.84 13.81 0.82 16.84 17.85 1.06 
7 18.23 18.96 1.04 18.23 20.42 1.12 
8 18.48 17.74 0.96 18.48 16.45 0.89 
9 16.73 18.90 1.13 16.73 15.39 0.92 
10 18.47 15.88 0.86 18.47 17.92 0.97 
GROUP B 
 
S.NO 
CEJ – RA  
CF 6 
CEJ – RA  
CF 1 
BASELINE 6 MONTHS BASELINE 1 YEAR 
1 18.25 19.16 1.05 18.25 17.16 0.94 
2 17.64 19.76 1.12 17.64 18.52 1.05 
3 17.93 17.21 0.96 17.93 20.26 1.13 
4 16.97 17.99 1.06 16.97 16.29 0.96 
5 18.24 18.60 1.02 18.24 17.15 0.94 
6 17.35 15.96 0.92 17.35 16.14 0.93 
7 17.89 17.53 0.98 17.89 18.96 1.06 
8 16.72 14.04 0.84 16.72 15.55 0.93 
9 18.58 18.95 1.02 18.58 16.54 0.89 
10 17.79 16.19 0.91 17.79 17.61 0.99 
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TABLE 5A: 
PLAQUE INDEX AND GINGIVAL BLEEDING INDEX 
 
PARAMETER 
(MEAN ±SD) 
BASELINE 6 MONTHS 1 YEAR 
PI 2.30±0.39 0.88±0.27 0.47±0.12 
GBI 76.83±6.54 21.02±6.57 9.74±2.17 
 
 
TABLE 5B: 
PROBING DEPTH & CLINICAL ATTACHMENT LEVEL: 
GROUP A 
 
PARAMETERS 
(Mean ±SD) 
BASELINE 6 MONTHS 1 YEAR 
PPD 8.0 ± 2.05 3.6 ± 1.35 2.2 ± 0.92 
CAL 8.9 ± 2.08 4.9 ± 1.97 3.5 ± 1.72 
GROUP B 
 
PARAMETERS 
(Mean ±SD) 
BASELINE 6 MONTHS 1 YEAR 
PPD 7.0 ± 1.83 3.9 ± 1.60 2.7 ± 0.95 
CAL 8.3 ± 1.94 6.0 ± 2.16 4.9 ± 1.52 
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TABLE 6A: INTRAGROUP COMPARISON:  
PLAQUE INDEX & GINGIVAL BLEEDING INDEX: 
 
TIME INTERVAL 
PLAQUE INDEX GINGIVAL BLEEDING 
INDEX 
Mean 
difference 
P value Mean 
difference 
P value 
Baseline - 6 months 1.42 0.000* 55.81 0.000* 
6 months - 1 year 0.41 0.000* 11.28 0.000* 
 
TABLE 6B: PERIODONTAL PROBING DEPTH 
 
TIME INTERVAL 
GROUP A GROUP B 
Mean 
difference 
P value Mean 
difference 
P value 
Baseline - 6 months 4.40 0.000* 3.10 0.000* 
6 months - 1 year 1.40 0.002* 1.20 0.003* 
 
TABLE 6C: CLINICAL ATTACHMENT LEVEL 
 
TIME INTERVAL 
GROUP A GROUP B 
Mean 
difference 
P value Mean 
difference 
P value 
Baseline - 6 months 4.00 0.000* 2.30 0.000* 
6 months - 1 year 1.40 0.002* 1.10 0.010* 
 
*Statistically significant (p˂0.05) 
Repeated measures ANOVA for intra group comparison 
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TABLE 7: INTERGROUP COMPARISON 
CLINICAL PARAMETERS: 
PARAMETER TIME FRAME Mean Difference p value 
(Group A Vs Group B) 
 
Periodontal 
probing depth 
(PPD) 
Baseline 1.0 0.26 
6 months -0.3 0.65 
1 year -0.5 0.25 
 
Clinical attachment 
level (CAL) 
Baseline 0.6 0.51 
6 months -1.1 0.25 
1 year -1.4 0.07 
 
Independent sample t test for intergroup comparisons. 
Statistically non-significant (p˃0. 05) 
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TABLE 8: INTRAGROUP COMPARISONS 
RADIOGRAPHIC PARAMETERS 
 
*Statistically significant (p˂0.05) 
Paired sample t test for intragroup comparisons 
 
GROUP A 
PARAMETERS (Mean ±SD) p value 
6 MONTHS 1 YEAR 
Bone fill  
(BF) 
4.52 ± 2.01 6.71 ± 1.77 0.000* 
Bone fill percentage 
(BF%) 
41.46 ± 15.79 62.92 ± 11.38 0.001* 
Bone crest change 
 (BCC) 
0.98 ± 0.57 1.79 ± 0.77 0.000* 
Bone crest change 
percentage (BCC%) 
27.39 ± 14.90 50.64 ± 16.68 0.000* 
Defect resolution 
 (DR) 
3.53 ± 1.76 4.92 ± 1.39 0.002* 
Defect resolution 
percentage (DR%) 
47.76 ± 19.12 68.80 ± 9.05 0.004* 
GROUP B 
PARAMETERS (Mean ±SD) p value 
6 MONTHS 1 YEAR 
Bone fill 
 (BF) 
2.23 ± 1.11 4.16 ± 1.37 0.001* 
Bone fill percentage 
(BF%) 
23.16 ± 9.26 41.52 ± 8.97 0.001* 
Bone crest change 
 (BCC) 
0.54 ± 0.29 1.11 ± 0.40 0.001* 
Bone crest change 
percentage (BCC%) 
14.08 ± 7.14 30.03 ± 13.53 0.002* 
Defect resolution 
 (DR) 
1.79 ± 1.10 3.05 ±1.56 0.009* 
Defect resolution 
percentage (DR%) 
28.31 ± 14.31 47.61 ± 14.96 0.009* 
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TABLE 9: INTERGROUP COMPARISONS 
RADIOGRAPHIC PARAMETERS 
PARAMETER TIME 
FRAME 
Mean Difference  
(Group A Vs group B) 
p value 
Bone fill (BF) 6 months 2.19 0.007* 
1 year 2.56 0.002* 
Bone fill percentage 
(BF%) 
6 months 18.29 0.005* 
1 year 21.40 0.000* 
Bone crest change 
(BCC) 
6 months 0.44 0.043* 
1 year 0.69 0.022* 
Bone crest change 
percentage (BCC%) 
6 months 13.31 0.020* 
1 year 20.61 0.007* 
Defect resolution (DR) 6 months 1.74 0.016* 
1 year 1.86 0.011* 
Defect resolution 
percentage (DR%) 
6 months 19.44 0.019* 
1 year 21.20 0.001* 
 
*Statistically significant (p˂0.05) 
Independent sample t test for intergroup comparisons 
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Figure 6: Comparison of mean score in Plaque index (PI) at Baseline, 
6 months and 1 year  
 
 
 
Figure 7: Comparison of mean score in Gingival bleeding index at 
Baseline, 6 months and 1 year  
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Figure 8: Comparison of Probing pocket depth (mm) between Group 
A and Group B  
 
 
 
Figure 9: Comparison of Clinical attachment level (mm) between 
Group A and Group B  
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Figure 10: Comparison of Clinical parameters 
 
 
 
Figure 11: Comparison of Bone fill percentage between Group A and 
Group B 
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Figure 12: Comparison of Bone crest change percentage between 
Group A and Group B 
 
 
 
Figure 13: Comparison of Defect resolution percentage between 
Group A and Group B 
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Figure 14: Comparison of Radiographic parameters 
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DISCUSSION 
The last two decades of periodontal therapy has perceived a significant 
progress in various aspects. A complete shift of resective pocket eradicative 
procedures to techniques and methods aimed at regeneration and conservation of the 
periodontium has been obtained. Bone being the crux of periodontal disease has 
evidently received lot of attention.
70
 
A wide array of new materials has been used for promoting periodontal 
regeneration in intraosseous defects. The bone replacement grafts provide 
regeneration through conductive or inductive processes and in combination with 
growth factors, have the potential to optimize the outcome of periodontal 
regeneration.
51 
Till date no graft material has been proven as a gold standard in the 
treatment of intrabony defects. However in a systematic review Trombelli et al
71 
have 
concluded that the use of specific biomaterials/bone grafts was more effective than 
open flap debridement in improving attachment levels in intraosseous defects. 
In the present study Bovine porous bone mineral (Geistlich Bio-Oss
®
)
 
was the 
graft material used. Like in earlier studies
72
 bovine porous bone mineral exhibited 
favourable handling properties such as: 
1. Ease of delivery to the site, 
2. Ease of condensing the material into the defect, 
3. Ability of the material to demonstrate an adhesion once placed in the defect, 
even with significant haemorrhage of the wound site, providing a stable graft. 
Polypeptide growth factors are one of the fundamental elements in tissue 
engineering, which have shown an important role in the growth and differentiation of 
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cells involved in periodontal wound healing.
73,74
 Platelets, a major resource of 
autogenous growth factors, are among the first cells to reach a wound site and initiate 
the healing process. 
Platelet-rich plasma (PRP) was the first generation of platelet gel used in 
periodontal regeneration therapy.
35,75,76,77
 While the potential benefits of this 
procedure have been critiqued, many of the discrepancies are likely more related to 
the lack of suitable methodological standardization and definition of the different PRP 
preparations than to any functional inadequacies, as the protocols and biological and 
surgical techniques used in the administration of the PRPs differ widely between 
study groups.
78,79
 
Platelet-rich fibrin (PRF), the second generation of platelet concentrate products, 
exhibits the same properties as PRP with the advantages of osteogenicity, a simple 
preparation process and a lack of bovine thrombin and anticoagulants, as it is 
produced from autologous blood.
31,37,80
 
Unlike PRF, CGF use variable rpm from 2400-3000 rpm to separate cells in the 
venous blood, therefore, results in fibrin rich blocks that are much larger, denser and 
richer in growth factors than common PRF. This shows superior regenerative capacity 
and higher versatility when using the fibrin rich block. According to Rodella
8
, CGF 
shows higher tensile strength, more growth factors, higher viscosity and higher 
adhesive strength than PRF. So surgeons can use CGF as barrier membrane to 
accelerate soft tissue healing or be mixed with bone graft to accelerate bone and soft 
tissue regeneration. 
One major criterion for periodontal regeneration is the maintenance of a wound 
space for the periodontal ligament cells to migrate into. For growth factors to exert 
their potential, they require a medium that can provide this space, and thus cell 
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induction and differentiation can be obtained. Marx et al
35
 demonstrated a 1.62 to 
2.16 fold increase in bone maturation using autologous platelet preparation in 
combination with a bone graft compared to bone graft alone in large human 
mandibular defects. However, only one study has focused on the application of CGF 
in combination with bone graft till date, evaluating the treatment outcomes in intra-
bony defects.
92
 
The present study was designed to evaluate the effectiveness of CGF with a BG 
when compared to BG alone. For this purpose, a total of 20 sites in 10 patients were 
taken in a split mouth design for the study. 
Only 3-wall and combined intrabony defects were selected because the number of 
remaining bony walls were found to be correlated positively with regeneration 
potential in grafting procedures.
81,82
 In addition, 3-wall defects provide the best spatial 
relationship for defect bridging by vascular and cellular elements from the periodontal 
ligament and adjacent osseous wall.
83
 
Defect morphology plays a vital role in healing after periodontal-regenerative 
treatment of intrabony defects. This was demonstrated in studies showing that the 
depth of the intrabony component of the defect influenced the amount of clinical 
attachment and bone gained at 1 year: the deeper the defect, the greater was the 
amount of clinical improvement.
84-88
  However, in a multicenter controlled study, it 
was demonstrated that deep and shallow defects have the ‘same potential’ for 
regeneration.
89
 
The uneventful healing and the lack of adverse reactions post-operatively 
suggested that BG and CGF used were tolerated well and in line with observation 
from previous studies that failed to show any foreign body reaction during initial 
healing and thereafter in the 6-month and 1 year evaluation period.
27,28,59,62
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On evaluating the clinical parameters, mean plaque score and gingival bleeding 
score were 2.30 & 76.83% respectively. The plaque index and the gingival bleeding 
index showed statistically significant difference 6 months (0.88 & 21.02%) and 1 year 
(0.47 & 9.74) with p=0.000 respectively. These results were in accordance with the 
studies by Yukna et al 
90
 and Srikanth et al
91
 who observed that patients undergoing 
periodontal therapy try to maintain optimal oral hygiene. 
The mean probing depth at baseline in group A and group B were 8.0mm and 
7.0mm respectively. Significant reduction in periodontal probing depth (PPD) were 
observed in both group A and group B at 6 months (3.6mm and 3.9mm) and 1 year 
(2.2mm and 2.7mm) respectively. But the intergroup comparison showed no 
statistically significant difference between two groups. The reduction in pocket depth 
was better than a 1 year follow up study conducted by Qiao J et al
92 
in thirty-one 
intrabony defects treated with CGFs + BPBM or BPBM alone  which was 3.1mm and 
4.5mm respectively. Similar results were obtained in a study by Sezgin Y et al
93
 on 
effects of platelet-rich fibrin (PRF) on healing of intra-bony defects treated with 
anorganic bovine bone mineral (ABBM) in which the reduction in pocket depth in 6 
months was 2.53mm and 2.86 mm respectively.  
Similarly in the present study significant reduction in clinical attachment level 
(CAL) were observed in both group A and group B at 6 months (4.9mm and 6.0mm) 
and 1 year (3.5mm and 4.9mm) from baseline (8.9mm and 8.3mm)  respectively. But 
the intergroup comparison showed no statistically significant difference between two 
groups. These results were in accordance with the study conducted by Qiao J et al
92
 
which was 2.4 ± 1.1 mm and 3.7 ± 1.3 mm respectively. Also the results were similar 
with results obtained by Sezgin Y et al
93
 with CAL of 3.86mm and 4.46mm 
respectively. 
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When evaluating the radiographic parameters,in the present study on intragroup 
comparison, the bone fill percentage showed statistically significant values in group A 
and group B when compared at  6 months (41.46 % & 23.16%), and 1 year (62.92% 
& 41.52%)  with p=0.001 respectively. Moreover on intergroup comparison at 6 
months and one year group A was found to be statistically highly significant than 
group B with p=0.005 and p=0.000 respectively. The results of the present study are 
in accordance with previous study by Lekovic et al
54 
which showed a defect fill of 
4.06 ± 0.87mm on buccal and 3.94 ± 0.73 on lingual sites in PRF + BPBM (Bovine 
porous bone mineral) compared to PRF group (2.21 ± 0.68 mm on buccal and 2.06 ± 
0.64 mm on lingual sites). Agarwal et al
94
 reported that PRF + DFDBA 
(demineralized freeze-dried bone allograft) showed a mean bone fill of 3.50 ± 0.67 
mm compared to DFDBA (2.49 ± 0.64 mm). Chandradas ND et al
57 
reported a bone 
fill% of 61.53% and 49.6% in PRF+DBM and PRF groups respectively which was in 
accordance with the present study.  
On intragroup comparison of the bone crest change percentage showed 
statistically significant values in both group A and group B when compared on 6 
months (27.39% & 14.08%)  and 1 year (50.64% & 30.02%)  with p=0.000 & 0.002 
respectively. Moreover on intergroup comparison at 6 months and one year group A 
was found to be statistically highly significant than group B with p=0.02 and p=0.007 
respectively. 
When evaluating the intragroup comparison of the defect resolution percentage 
showed statistically significant values in both group A and group B when compared 
on 6 months (47.76% & 28.31%)  and 1 year (68.8% & 47.61%)  with p=0.004 & 
0.009 respectively. Moreover on intergroup comparison at 6 months and one year 
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group A was found to be statistically highly significant than group B with p=0.019 
and p=0.001 respectively. 
In the present study CGF+BPBM group demonstrated better results in clinical and 
radiographic parameters than BPBM alone in the management of periodontal 
intrabony defects. None of the above mentioned studies discussed about bone crest 
change and defect resolution.
54,57,92,93,94
 In the present study bone crest change and 
defect resolution has been calculated. This result may be attributed to the additional 
beneficial effects of CGF.  
Although good intra-examiner reproducibility was obtained, the re-entry 
measurement is still the ‘gold standard’ to reflect actual bone change; and periapical 
radiography is inherently limited in its ability to evaluate true bone level. However, 
future long-term clinical and histological studies with larger sample size should be 
undertaken to determine the efficacy of bovine porous bone mineral in combination 
with concentrated growth factor in the treatment of intrabony defects. Thus in future, 
CGF may prove to be a novel adjunct to conventional regenerative methods in 
management of periodontal osseous defects. 
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SUMMARY AND CONCLUSION 
The present study was conducted in order to evaluate the effectiveness of 
concentrated growth factor in combination with Bovine porous bone mineral as 
compared to Bovine porous bone mineral alone in the treatment of periodontal 
intrabony defects. A total of twenty defects in ten patients were selected for the study. 
The defects were randomly divided into two groups to receive CGF + BPBM and 
BPBM alone. Thus each group had ten defects. The clinical and radiographic data 
were assessed over a period of 6 months and 1 year and the values were subjected to 
statistical analysis. 
The following conclusions were drawn from the study: 
 Both CGF + BPBM and BPBM were well tolerated by the periodontal tissues 
during the course of the study. 
 There was a definite improvement in the clinical and radiographic parameters 
in both groups, i.e. CGF + BPBM and BPBM from baseline to 6 months and 1 
year. 
 Radiographic evidence of bone fill, alveolar crest change and defect resolution 
were observed in both the groups. The difference at the end of 6 months and 1 
year were statistically significant in both the groups.  
 Addition of CGF revealed its beneficial effect in the combination group 
(CGF+BPBM) with evidence of significant increase in bone fill, alveolar crest 
change and defect resolution at 6 months and 1 year when compared to BPBM 
alone.  
The outcomes of regenerative periodontal therapy are dependent on multiple 
factors such as patient selection, defect selection, choice of diagnostic and therapeutic 
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modalities and post-operative follow up period. Therefore all these factors should be 
taken into consideration during decision making. 
Within the limits of the present study, it can be concluded that both the treatment 
modalities were effective in improving the clinical as well as radiographic parameters. 
The addition of Concentrated growth factor to Bovine porous bone mineral has 
demonstrated successful and promising results. Thus in future, clinical trials with 
larger sample size may be employed to further explore the potential benefits of CGF 
as a grafting material. 
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ANNEXURE - 1 
PARTICIPANT INFORMATION SHEET 
 
Investigator: DR.S.RUBINE 
Guide          : DR.JAISHREE TUKARAM KSHIRSAGAR, MDS 
Title: EVALUATION OF EFFECTIVENESS OF CONCENTRATED GROWTH 
FACTOR WITH BOVINE POROUS BONE MINERAL AS COMPARED TO 
BOVINE POROUS BONE MINERAL ALONE IN THE TREATMENT OF 
INTRA BONY DEFECTS – A SPLIT MOUTH STUDY 
Name of the research institution: Tamil Nadu Government Dental College and Hospital, 
Chennai 
The investigator, Dr. S.RUBINE under the guidance of   Dr. JAISHREE TUKARAM 
KSHIRSAGAR, MDS is conducting a study as titled above with aim to do an evaluation of 
effectiveness of concentrated growth factor with bovine porous bone mineral as compared to 
bovine porous bone mineral alone in the treatment of intra bony defects  
1. Procedure: the following examinations and investigations will be done for you. 
 Intraoral examination, Extra oral examination 
 Blood test –  7ml of blood ( 1 table spoon)  will be drawn from your hand 
 X-ray will be taken for the diseased site with protection (lead apron , thyroid 
collars ) 
 Model of your teeth will be prepared by taking alginate impression 
 Deposits on your teeth will be cleaned with ultrasonic scaler and hand 
instrument.  
 Surgery will be done in diseased site by raising the gums and cleaning the 
root part of the teeth with hand instruments and salt water irrigation will be 
done and the intended material will be placed and the gums will be 
repositioned and stitched with suture material.  
 Clinical evaluation will be performed at baseline, 3 months and 6 months and 
9 months after the procedure and radiological evaluation will be performed at 
baseline, 6 months and 9 months after the procedure.  
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2. Risk of  participation: 
 Patients may be allergic to LA or the material used in the study. 
 Patient may experience pain, discomfort, swelling following the procedure. 
 Patient will be exposed to radiation while taking radiographs during study. 
3. Benefits of participation:  
Patients will be treated for improving the periodontal status and minimizing alveolar 
bone loss. 
 
4. Confidentiality : 
The identity of the patients participating in the research will be kept 
confidential throughout the study. In the event of any publication or 
presentation resulting from the research, no personally identifiable 
information will be shared. 
 
5. Participants right : 
Taking part in the study is voluntary. You are free to decide whether to 
participate in the study or to withdraw at any time; your decision will not result in any 
loss of benefits to which you are otherwise entitled. The results of this study will be 
intimated to you at the end of the study period or during the study if anything is found 
abnormal which may aid in the management or treatment. 
 
6. Compensation: Nil 
 
7. Contacts:  
 
 
For queries related to the study: 
Primary Investigator:  
Dr.S.RUBINE 
PG Student 
Department of Periodontics 
Tamilnadu Govt. Dental College & Hospital 
Chennai- 600 003        
Mobile – 9789800598 
Contact details regarding rights of the 
participant: 
Dr. B. Saravanan, MDS,PhD, 
The Chairperson, 
Institutional Ethical committee 
Tamilnadu Govt. Dental College & Hospital, 
Chennai-600 003. 
 
 
MuhŒ¢á x¥òjš got« 
Muha¢áÆ‹ jiy¥ò 
gšnt® gFâ vY«ò njŒkhd¤âš FÉ¥ò ts®¢á fhuÂ k‰W« kh£L 
E©Âa vY«ò jhJ M»at‰iw ïiz¤J ga‹gL¤â k‰W« kh£L 
E©Âa vY«ò jhJit k£L« ga‹gL¤â ÛSUth¡f« âw‹ kâ¥ÕL- kÅj 
ãÇthŒ MŒî 
bga®      òwnehahË v©  
taJ/ ghš     MuhŒ¢á nr®¡if v© 
KftÇ 
bjhiyngá 
eh‹ ............................................... taJ ............... v‹Dila Ra 
ÃidîlD« k‰W« KG Rjªâu¤JlD« ïªj kU¤Jt MuhŒ¢áÆš 
v‹id nr®¤J¡bfhŸs x¥òjš mË¡»nw‹. 
Ñœfhz¥gL« ÃgªjidfS¡F eh‹ r«kâ¡»nw‹. 
• eh‹ ïªj MuhŒ¢áÆ‹ neh¡f« k‰w« brašKiwfŸ g‰¿ 
KGikahf bjÇÉ¡f¥g£LŸns‹. 
• eh‹ ïªj MŒî¡fhf <W mWit á»¢ir brŒJbfhŸs 
nt©oajhf m¿»nw‹. 
• á»¢irÆ‹nghJ FÉ¥ò ts®¢á fhÇ k‰W« kh£L E©Âa vY«ò 
jhJ M»at‰iw ïiz¤J ga‹gL¤j r«kâ¡»nw‹. 
• v‹ clš ey« ghâ¡¥g£lhnyh mšyJ vâ®ghuhj tH¡f¤â‰F khwhd 
nehŒF¿fŸ bj‹g£lhnyh mj‰F á»¢ir bg‰W¡bfhŸtj‰F« KG 
cÇik cŸsjhf m¿»nw‹. 
• eh‹ V‰fdnt c£bfh©l k‰W« c£bfhŸ»‹w kUªJfË‹ 
Égu§fis MuhŒ¢áahsÇl« bjÇÉ¤JŸns‹. 
• v‹ kU¤Jt F¿¥ngLfis ïªj MuhŒ¢áÆš ga‹gL¤â¡bfhŸs 
r«kâ¡»nw‹. ïªj MuhŒ¢á ikaK« MuhŒ¢áahsU« v‹Dila 
Égu§fŸ mid¤ijí« ïufáakhf it¥gjhf m¿»nw‹. 
 
 
 
.................................... 
neahËÆ‹ bga® 
.................................... 
ifbah¥g« 
.................................... 
njâ 
   
.................................... 
MuhŒ¢áahs® bga® 
.................................... 
ifbah¥g« 
.................................... 
njâ 
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MuhŒ¢á g‰¿a jftš got« 
MuhŒ¢á nk‰bfhŸgt® tÊel¤Jgt® 
kU.brs.%ãÅ kU.b#Œ$J¡fMuh« ø®rhf®, v«.o.v°.  
MuhŒ¢á ÃWtd¤â‹ bga®:  jÄœehL muR gš kU¤Jt¡ fšÿÇ k‰W« 
kU¤Jtkid, br‹id. 
Muha¢áÆ‹ jiy¥ò 
gšnt® gFâ vY«ò njŒkhd¤âš FÉ¥ò ts®¢á fhuÂ k‰W« 
kh£L E©Âa vY«ò jhJ M»at‰iw ïiz¤J ga‹gL¤â k‰W« 
kh£L E©Âa vY«ò jhJit k£L« ga‹gL¤â ÛSUth¡f« âw‹ 
kâ¥ÕL- kÅj ãÇthŒ MŒî 
MuhŒ¢áÆ‹ neh¡f« 
gš nt® gFâ vY«ò njŒkhd¤âš FÉ¥ò ts®¢á fhuÂ k‰W« 
kh£L E©Âa vY«ò jhJ M»at‰iw ïiz¤J xUòw« ga‹gL¤â 
k‰W« kWòw« kh£L E©Âa vY«ò jhJit k£L« ga‹gL¤â 
kâ¥ÕLfis mWit á»¢ir¡F K‹, 3 khj§fS¡F ã‹, 6 khj§fS¡F 
ã‹ k‰W« 9 khj§fS¡F ã‹ k‰W« fâÇa¡f kâ¥ÕLfis mWit 
á»¢ir¡F K‹, 6 khj§fS¡F ã‹ k‰W« 9 khj§fS¡F ã‹ MŒî 
brŒjš. 
brŒKiw 
Ñœf©l MŒîfŸ gÇnrhjidfŸ c§fS¡F brŒa¥gL«. 
• thŒ gÇnrhjid 
o c£òw« 
o btË¥òw« 
• tH¡fkhd ïu¤j¥ gÇnrhjid 
• c§fË‹ iffËÈUªJ ïu¤j¥ gÇnrhjid¡fhf 7Ä.È. msî (xU 
nki#¡ fu©o msî) ïu¤j« vL¡f¥gL«. 
• x›thik V‰gL»wjh v‹gij bjÇªJbfhŸs 0.5Ä.È 2% 
È¡ndhbfÆ‹ ka¡f kUªJ c§fË‹ ifÆš gÇnrhjid¡fhf 
brY¤j¥gL«. ã‹ò nehí‰w gFâÆš ka¡f kUªJ bfhL¡f¥gL«. 
• mš£uh nrhÅ¡ °nfy® k‰W« if¡fUÉfŸ ga‹gL¤â gš k‰W« 
gšÈ‹ nt® R¤j« brŒa¥gL«. c¥òÚ® bfh©L nehí‰w gFâ R¤j« 
brŒa¥gL«. 
• FÉ¥ò ts®¢á fhuÂ k‰W« kh£L E©Âa vY«ò jhJ M»at‰iw 
ïiz¤J ga‹gL¤j¥gL«.  
• kU¤Jt kâ¥ÕL mWit á»¢ir¡F K‹, 3 khj§fS¡F ã‹, 6 
khj§fS¡F ã‹ k‰W« 9 khj§fS¡F ã‹  k‰W« fâÇa¡f kâ¥ÕL 
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mWit á»¢ir¡F K‹, 6 khj§fS¡F ã‹ k‰W« 9 khj§fS¡F 
ã‹ brŒa¥gL«. 
g§nf‰gâdhš tu¡Toa g¡f ÉisîfŸ  
tÈ, å¡f« k‰W« ga‹gL¤J« bghU£fËdhš áy neu§fËš 
x›thik V‰gl thŒ¥ò©L. mj‰fhf njit¥gL« kUªJfS« 
kU¤JtK« tH§f¥gL«. 
g§nf‰gâdhš Éisí« e‹ikfŸ 
c§fË‹ ehŸg£l gš <W nehŒ¡F á»¢ir mË¡f¥gL«. 
ïufáa fh¥ò 
c§fis¥ g‰¿a F¿¥òfŸ ãw® m¿ah t©z« MuhŒ¢á Koí« 
tiu ïufáakhf ghJfh¡f¥gL«. mij btË¥gL¤J« neu§fËš vªj 
jÅ milahs§fS« btË¥gl thŒ¥ò »ilahJ. 
j‹dh®t g§nf‰ò 
ïªj MuhŒ¢áÆš g§FbgWtJ j§fË‹ jÅ¥g£l Koî k‰W« 
ïªj MuhŒ¢áÆš ïUªJ Ú§fŸ v¥nghJ nt©LkhdhY« 
Éy»¡bfhŸsyh«. j§fË‹ ïªj âO® Koî c§fS¡nfh mšyJ 
MuhŒ¢áahsU¡nfh vªjÉj ghâ¥ò« V‰gL¤jhJ v‹gij 
bjÇa¥gL¤J»nwh«. 
 
 
 
 
nehahËÆ‹ bga® ifbah¥g«/ ifnuif 
 
 
 
 
 
MuhŒ¢á bjhl®òila jftšfS¡F 
kU.brs.%ãÅ 
g£l nk‰go¥ò khzÉ, 
jÄœehL muR gš kU¤Jt¡ fšÿÇ 
kU¤Jtkid, br‹id-3. 
brš: 978900598 
g§nf‰ghsÇ‹ cÇik bjhl®òila 
jftšfS¡F:  
kU.ã.rutz‹ MDS, Ph.D., 
jiyt®, ÃWtd be¿KiwfŸ FG, 
jÄœehL muR gš kU¤Jt¡ fšÿÇ 
k‰W« kU¤Jtkid, br‹id-3. 
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ANNEXURE - 3 
 
INFORMED CONSENT FORM 
 
EVALUATION OF EFFECTIVENESS OF CONCENTRATED GROWTH 
FACTOR WITH BOVINE POROUS BONE MINERAL AS COMPARED TO 
BOVINE POROUS BONE MINERAL ALONE IN THE TREATMENT OF 
INTRA BONY DEFECTS – A SPLIT MOUTH STUDY 
Participant ID No: 
 
“I have read the foregoing information, or it has been read to me. I have had the 
opportunity to ask questions about it and any questions I have asked have been 
answered to my satisfaction. I consent voluntarily to participate as a participant 
in this study and understand that I have the right to withdraw from the study at 
any time without in any way it affecting my further medical care.” 
 
 
_______________         _________________                  __________________ 
Date                                   Name of the participant       Signature/thumb  impression     
                                                                                                             Of the participant   
 
 
[The literate witness selected by the participant must sign the informed consent form. The 
witness should not have any relationship with the research team; If the participant doesn’t 
want to disclose his / her participation details to others, in view of respecting the wishes of 
the participant, he / she can be allowed to waive from the witness procedure (This is 
applicable to literate participant ONLY). This should be documented by the study staff by 
getting signature from the prospective participant] 
 
_____________________________________________________________________________________________   
 
 
“I have witnessed the accurate reading of the consent form to the potential 
participant and the individual has had opportunity to ask questions. I confirm 
that the individual has given consent freely” 
 
______________                         __________________                  _______________ 
Date                                                   Name of the witness                       Signature of the                   
interviewer 
 
______________                        ___________________                 _______________  
    Date                                                  Name of the witness          Signature of the   
                                                                  interviewer 
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ANNEXURE - 5 
 
DEPARTMENT OF PERIODONTICS 
TAMILNADU GOVERNMENT DENTAL COLLEGE AND HOSPITAL 
CHENNAI – 600003 
 
 
 “EVALUATION OF EFFECTIVENESS OF CONCENTRATED GROWTH 
FACTOR WITH BOVINE POROUS BONE MINERAL AS COMPARED TO 
BOVINE POROUS BONE MINERAL ALONE IN THE TREATMENT OF 
INTRA BONY DEFECTS –A SPLIT MOUTH STUDY” 
PROFORMA FOR TREATMENT GROUP 
 
 
Date:     O.P. No:                                Group no: 
  
 
Name:                Age / Sex:              Case no: 
                                                                                 
Address:        Tel no:             Mobile no: 
 
                                                            Occupation:                          Income: 
  
 
 
Chief Complaint    : 
 
 
 
 
History of presenting illness   : 
 
 
 
 
 
 
Past Medical History  : 
 
 
 
 
Past Dental History   : 
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Personal history:  
                                  
    1. Habits:      
     
    2. Oral hygiene: 
 
    3. Menstrual history: 
 
 
 
Clinical Examination: 
 
 
EXTRAORAL EXAMINATION: 
 
      1. Facial symmetry   
                           
      2. Lymph node status 
   
 
INTRA ORAL EXAMINATION: 
 
    1. Hard tissue examination: 
 
    2. Gingival examination:  
 
  Colour                         Contour                        Consistency 
 
  Position                       Texture                          
 
  Bleeding on probing 
 
  Exudate 
 
 
 PERIODONTAL EXAMINATION:  
 
 
 
1. PLAQUE INDEX-SILNESS&LOE (1964) 
 
                
18  17 16 15 14 13 12 11 21 22 23 24 25 26 27 28 
48 47 46 45 44 43 42 41 31 32 33 34 35 36 37 38 
                
 
Score: 
 
Calculation:                                                                                     Interpretation: 
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2. GINGIVAL BLEEDING INDEX (AINAMO & BAY 1975) 
 
                
18  17 16 15 14 13 12 11 21 22 23 24 25 26 27 28 
48 47 46 45 44 43 42 41 31 32 33 34 35 36 37 38 
                
 
Score: 
 
Calculation:                                                                                      Interpretation: 
 
 
 
3. PROBING DEPTH (PD) & CLINICAL ATTACHMENT LEVEL (CAL) 
(mm) 
 
  MAXILLARY  
                                           PALATAL 
CAL                 
PD                 
 18 17 16 15 14 13 12 11 21 22 23 24 25 26 27 28 
PD                 
CAL                 
                                            BUCCAL     
 
MANDIBULAR 
 
                                            LINGUAL 
CAL                 
PD                 
 18 17 16 15 14 13 12 11 21 22 23 24 25 26 27 28 
PD                 
CAL                 
                                           BUCCAL 
 
 
4. INVESTIGATIONS: 
 
Blood investigations: 
 
 
 
 
Radiological assessment: 
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Others: 
 
 
 
5. Diagnosis: 
 
 
 
 
6. Prognosis: 
 
 
 
 
 
TREATMENT: 
 
 
1. EMERGENCY / PRELIMINARY: 
 
 
 
 
 
 
 
2. PHASE I: 
 
 
 
 
 
 
3. RE-EVALUATION AFTER PHASE I THERAPY: 
 
 
 
 
4. CLINICAL SITE SELECTED FOR STUDY: 
 
 
 
 
5. PHASE II: (SURGICAL) 
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6. PHASE III: 
 
 
 
 
 
 
 
7. PHASE IV :( RE-EVALUATION) 
 
 
 
 
 
 
 
CLINICAL EVALUATION: 
 
  
Duration  SITE A SITE B 
PPD CAL PPD CAL 
Baseline      
6 months     
1 year     
 
 
 
 
RADIOGRAPHIC EVALUATION: 
 
USING IOPA WITH GRID:  
 
 
 
 
 
 
Duration  
SITE A SITE B 
CEJ - BD CEJ- AC AC-BD CEJ - BD CEJ- AC AC-BD 
Baseline        
6 months       
1 year       
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INFERENCE/RESULT: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Signature of the P.G. Student                                             Signature of the Guide 
 
 
Date: 
 
 
 
 
